Overcoming gene-delivery hurdles: Physiological considerations for nonviral vectors

Trends in Biotechnology

Volumn 34, Issue 2, 2016, Pages 91-105

  Hill, Andrew B ^a,b   Chen, Mingfu ^c   Chen, Chih Kuang ^d   Pfeifer, Blaine A ^a,c   Jones, Charles H ^a,c  

^a Abcombi Biosciences Inc   (United States)

^b The University of Texas at Austin   (United States)

^c the State University of New York   (United States)

^d FENG CHIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE TRANSFER; GENES; GENETIC ENGINEERING; MEDICAL APPLICATIONS; PATIENT TREATMENT; PHYSIOLOGY; STATISTICS; VECTORS;

BIOCHEMICAL MECHANISMS; CLINICAL TRANSLATION; DESIGN CONSIDERATIONS; ENGINEERING APPLICATIONS; NUCLEAR TRANSLOCATIONS; PHYSIOLOGICAL CONDITION; SEVERE COMBINED IMMUNE DEFICIENCIES; THERAPEUTIC EFFICACY;

GENE THERAPY;

BIOMATERIAL; NUCLEIC ACID; VIRUS VECTOR;

ANIMAL MODEL; BETA THALASSEMIA; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIABETES MELLITUS; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL DESIGN; FANCONI ANEMIA; GENE TARGETING; GENE THERAPY; GLIOBLASTOMA; GLYCOGEN STORAGE DISEASE TYPE 2; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LEBER CONGENITAL AMAUROSIS; LEBER HEREDITARY OPTIC NEUROPATHY; LENTIVIRINAE; LEUKEMIA; LIPOFUSCINOSIS; MALIGNANT PLEURA EFFUSION; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROVIRIDAE; REVIEW; SICKLE CELL ANEMIA; SOLID TUMOR; THALASSEMIA; WISKOTT ALDRICH SYNDROME; DRUG DELIVERY SYSTEM; GENE VECTOR; PROCEDURES;

DRUG DELIVERY SYSTEMS; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84961248117     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.11.004     Document Type: Review

References (116)

1. Jones C.H., et al. Overcoming nonviral gene delivery barriers: perspective and future. Mol. Pharm. 2013, 10:4082-4098.
2. Ginn S.L., et al. Gene therapy clinical trials worldwide to 2012 - an update. J. Gene. Med. 2013, 15:65-77.
3. Jones C.H., et al. Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design. J. Mater. Chem. B 2014, 2:8053-8068.
4. Yin H., et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15:541-555.
5. Schlenk F., et al. Recent developments and perspectives on gene therapy using synthetic vectors. Ther. Deliv. 2013, 4:95-113.
6. Alex S.M., Sharma C.P. Enhanced intracellular uptake and endocytic pathway selection mediated by hemocompatible ornithine grafted chitosan polycation for gene delivery. Colloids Surf. B Biointerfaces 2014, 122:792-800.
7. Vighi E., et al. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int. J. Pharm. 2010, 389:254-261.
8. Xiao B., et al. A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery. J. Biomed. Mater. Res. A 2013, 101:1888-1897.
9. Jia F., et al. A nonviral minicircle vector for deriving human iPS cells. Nat. Methods 2010, 7:197-199.
10. Gracey Maniar L.E., et al. Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level. Mol. Ther. 2013, 21:131-138.
11. Lu J.M., et al. Mini-intronic plasmid (MIP) vector sequences enhance AAV-mediated transgene expression in vitro and in vivo. Mol. Ther. 2014, 22:S112-S113.
12. Lu J., et al. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol. Ther. 2013, 21:954-963.
13. Aurisicchio L., et al. A novel minigene scaffold for therapeutic cancer vaccines. Oncoimmunology 2014, 3:e27529.
14. Wang H.Y., et al. Tyroserleutide-based gene vector for suppressing VEGF expression in cancer therapy. Biomaterials 2012, 33:8685-8694.
15. Sahay G., et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 2013, 31:653-658.
16. Gu S., et al. The loop position of shRNAs and pre-miRNAs is critical for the accuracy of dicer processing in vivo. Cell 2012, 151:900-911.
17. Xue W., et al. Small RNA combination therapy for lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E3553-E3561.
18. Wang Z., et al. Biomimetic RNA-silencing nanocomplexes: overcoming multidrug resistance in cancer cells. Angew. Chem. 2014, 53:1997-2001.
19. Shin S., et al. FRET-based probing to gain direct information on siRNA sustainability in live cells: asymmetric degradation of siRNA strands. Mol. BioSyst. 2011, 7:2110-2113.
20. Layzer J.M., et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004, 10:766-771.
21. Yamamoto A., et al. Current prospects for mRNA gene delivery. Eur. J. Pharm. Biopharm. 2009, 71:484-489.
22. Li N., et al. Development of a cell system for siRNA screening of pathogen responses in human and mouse macrophages. Sci. Rep. 2015, 5:9559.
23. Fedorov Y., et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006, 12:1188-1196.
24. Chan J.H., et al. Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 2006, 33:533-540.
25. Lok C.N., et al. Potent gene-specific inhibitory properties of mixed-backbone antisense oligonucleotides comprised of 2'-deoxy-2'-fluoro-D-arabinose and 2'-deoxyribose nucleotides. Biochemistry-Us 2002, 41:3457-3467.
26. Sharma V.K., et al. Antisense oligonucleotides: modifications and clinical trials. Med. Chem. Comm. 2014, 5:1454-1471.
27. Yee J.K., Lin R.J. Antisense oligonucleotides shed new light on the pathogenesis and treatment of spinal muscular atrophy. Mol. Ther. 2012, 20:8-10.
28. Moore R., et al. CRISPR-based self-cleaving mechanism for controllable gene delivery in human cells. Nucleic Acids Res. 2015, 43:1297-1303.
29. Sander J.D., Joung J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 2014, 32:347-355.
30. Liang P., et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell 2015, 6:363-372.
31. Ahmad M.U., et al. Carbohydrate mediated drug delivery: synthesis and characterization of new lipid-conjugates. Chem. Phys. Lipids 2015, 186:30-38.
32. Seguin J., et al. Fine tuning of mixed ionic and hydrogen bond interactions for plasmid delivery using lipoplexes. Eur. J. Pharm. Biopharm. 2015, 90:63-69.
33. Lee D., et al. Bioreducible guanidinylated polyethylenimine for efficient gene delivery. Chem. Med. Chem. 2014, 9:2718-2724.
34. Islam M.A., et al. Major degradable polycations as carriers for DNA and siRNA. J. Control. Release 2014, 193:74-89.
35. Huschka R., et al. Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano 2012, 6:7681-7691.
36. Jensen S.A., et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. Sci. Transl. Med. 2013, 5:209ra152.
37. Cutler J.I., et al. Spherical nucleic acids. J. Am. Chem. Soc. 2012, 134:1376-1391.
38. Mirkin C.A., et al. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature 1996, 382:607-609.
39. Minami K., et al. siRNA delivery targeting to the lung via agglutination-induced accumulation and clearance of cationic tetraamino fullerene. Sci. Rep. 2014, 4:7.
40. Mishra S., et al. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur. J. Cell Biol. 2004, 83:97-111.
41. Park Y.C., et al. Effect of PEG molecular weight on stability, T(2) contrast, cytotoxicity, and cellular uptake of superparamagnetic iron oxide nanoparticles (SPIONs). Colloids Surf. B Biointerfaces 2014, 119:106-114.
42. Pannier A.K., et al. Surface polyethylene glycol enhances substrate-mediated gene delivery by nonspecifically immobilized complexes. Acta Biomater. 2008, 4:26-39.
43. Ikeda Y., Nagasaki Y. Impacts of PEGylation on the gene and oligonucleotide delivery system. J. Appl. Polym. Sci. 2014, 131:40293.
44. Petros R.A., DeSimone J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 2010, 9:615-627.
45. Kolhar P., Mitragotri S. Polymer microparticles exhibit size and shape dependent accumulation around the nucleus after endocytosis. Adv. Funct. Mater. 2012, 22:3759-3764.
46. Chu Z.Q., et al. Unambiguous observation of shape effects on cellular fate of nanoparticles. Sci. Rep. 2014, 4:4495.
47. Singh S., et al. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 2011, 28:2996-3015.
48. Parsa S., et al. A high-throughput comparison of recombinant gene expression parameters for E. coli-mediated gene transfer to P388D1 macrophage cells. J. Biotechnol. 2008, 137:59-64.
49. Parsa S., et al. A comparison between polymeric microsphere and bacterial vectors for macrophage P388D1 Gene Delivery. Pharm. Res. 2008, 25:1202-1208.
50. Chung T.C., et al. Improved Escherichia coli bactofection and cytotoxicity by heterologous expression of bacteriophage PhiX174 lysis gene E. Mol. Pharm. 2015, 12:1691-1700.
51. Jones C.H., et al. Polymyxin B treatment improves bactofection efficacy and reduces cytotoxicity. Mol. Pharm. 2013, 20:4301-4308.
52. Jones C.H., et al. Hybrid biosynthetic gene therapy vector development and dual engineering capacity. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12360-12365.
53. Jones C.H., et al. PEGylated cationic polylactides for hybrid biosynthetic gene delivery. Mol. Pharm. 2015, 12:846-856.
54. Jones C.H., et al. Influence of molecular weight upon mannosylated bio-synthetic hybrids for targeted antigen presenting cell gene delivery. Biomaterials 2015, 58:103-111.
55. Loeffler D.I., et al. Comparison of different live vaccine strategies in vivo for delivery of protein antigen or antigen-encoding DNA and mRNA by virulence-attenuated Listeria monocytogenes. Infect. Immun. 2006, 74:3946-3957.
56. Baban C.K., et al. Bacteria as vectors for gene therapy of cancer. Bioeng. Bugs 2010, 1:385-394.
57. Singh N., et al. Bioresponsive mesoporous silica nanoparticles for triggered drug release. J. Am. Chem. Soc. 2011, 133:19582-19585.
58. Guerrero-Cazares H., et al. Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo. ACS Nano 2014, 8:5141-5153.
59. Zhang Y., et al. In vivo gene delivery by nonviral vectors: overcoming hurdles?. Mol. Ther. 2012, 20:1298-1304.
60. Jones C.H., et al. Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation. Biomaterials 2015, 37:333-344.
61. Chen S.-H., Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest. 2011, 41:221-232.
62. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr. Opin. Mol. Ther. 2007, 9:248-257.
63. Li S.-D., et al. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol. Ther. 2008, 16:942-946.
64. Song E., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
65. Wang P., et al. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS ONE 2010, 5:e10202.
66. Kroll A., et al. Current in vitro methods in nanoparticle risk assessment: limitations and challenges. Eur. J. Pharm. Biopharm. 2009, 72:370-377.
67. Torubarova N.A., et al. Antigenic determinants on membranes and monocyte function]. Gematol. Transfuziol. 1988, 33:34-38.
68. Dane E.L., et al. Synthetic enantiopure carbohydrate polymers that are highly soluble in water and noncytotoxic. ACS Macro Lett. 2013, 2:887-890.
69. Kratz F., Elsadek B. Clinical impact of serum proteins on drug delivery. J. Control. Release 2012, 161:429-445.
70. Tseng Y.-C., et al. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 2009, 61:721-731.
71. Holland J.W., et al. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. Biochemistry 1996, 35:2618-2624.
72. Kim Y.H., et al. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J. Control. Release 2005, 103:209-219.
73. Yin L., et al. Reconfiguring the architectures of cationic helical polypeptides to control non-viral gene delivery. Biomaterials 2013, 34:2340-2349.
74. Gilleron J., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotech. 2013, 31:638-646.
75. Rehman Z.U., et al. Mechanism of polyplex- and lipoplex-mediated delivery of nucleic acids: real-time visualization of transient membrane destabilization without endosomal lysis. ACS Nano 2013, 7:3767-3777.
76. Brunner S., et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant adenovirus. Gene Therapy. 2000, 7:401-407.
77. Fassati A. HIV infection of non-dividing cells: a divisive problem. Retrovirology 2006, 3:74.
78. Govindarajan S., et al. Gene delivery into human cancer cells by cationic lipid-mediated magnetofection. Int. J. Pharm. 2013, 446:87-99.
79. Schaffer D.V., Lauffenburger D.A. Optimization of cell surface binding enhances efficiency and specificity of molecular conjugate gene delivery. J. Biol. Chem. 1998, 273:28004-28009.
80. Ogris M., et al. The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Therapy. 1998, 5:1425-1433.
81. van Gaal E.V.B., et al. How to screen non-viral gene delivery systems in vitro?. J. Control. Release 2011, 154:218-232.
82. Kastner E., et al. Microfluidic-controlled manufacture of liposomes for the solubilisation of a poorly water soluble drug. Int. J. Pharm. 2015, 485:122-130.
83. Lai W.F. Microfluidic methods for non-viral gene delivery. Curr. Gene Therapy. 2015, 15:55-63.
84. Lei P., et al. Cell-controlled and spatially arrayed gene delivery from fibrin hydrogels. Biomaterials 2009, 30:3790-3799.
85. Bellis A.D., et al. Dynamic transcription factor activity profiling in 2D and 3D cell cultures. Biotechnol. Bioeng. 2013, 110:563-572.
86. Bae Y.H., Park K. Targeted drug delivery to tumors: myths, reality and possibility. J. Control. Release 2011, 153:198-205.
87. Orcutt K.D., et al. Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol. Cancer Ther. 2012, 11:1365-1372.
88. Au J.L.S., et al. Determinants of drug delivery and transport to solid tumors. J. Control. Release 2001, 74:31-46.
89. Iyer A.K., et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11:812-818.
90. Wilke M., et al. Efficacy of a peptide-based gene delivery system depends on mitotic activity. Gene Therapy. 1996, 3:1133-1142.
91. McGonigle P., Ruggeri B. Animal models of human disease: challenges in enabling translation. Biochem. Pharmacol. 2014, 87:162-171.
92. Caldwell G.W., et al. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL Vss and t1/2 be predicted from in vivo rat data?. Eur. J. Drug Metab. Pharmacokinet. 2004, 29:133-143.
93. Fan J., de Lannoy I.A. Pharmacokinet. Biochem. Pharmacol. 2014, 87:93-120.
94. Bass A., et al. Origins, practices and future of safety pharmacology. J. Pharmacol. Toxicol. Methods 2004, 49:145-151.
95. Ahuja V., Sharma S. Drug safety testing paradigm, current progress and future challenges: an overview. J. Appl. Toxicol. 2014, 34:576-594.
96. Stevens J.L., Baker T.K. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 2009, 14:162-167.
97. Wolfe J.H. Gene therapy in large animal models of human genetic diseases. ILAR J. 2009, 50:107-111.
98. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
99. Achermann Y., et al. Immunoproteomic Identification of in vivo-produced propionibacterium acnes proteins in a rabbit biofilm infection model. Clin. Vaccine Immunol. 2015, 22:467-476.
100. Trevejo-Nunez G., et al. Ethanol impairs mucosal immunity against Streptococcus pneumoniae infection by disrupting interleukin 17 gene expression. Infect. Immun. 2015, 83:2082-2088.
101. Grossman T.H., et al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob. Agents Chemother. 2015, 59:2567-2571.
102. Mangraviti A., et al. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano 2015, 9:1236-1249.
103. Bae H., et al. Development of functional biomaterials with micro- and nanoscale technologies for tissue engineering and drug delivery applications. J. Tissue Eng. Regen. Med. 2014, 8:1-14.
104. Green J.J., et al. Poly (beta-amino esters): procedures for synthesis and gene delivery. Methods in Molecular Biology 2009, 53-63. Humana Press. M. Belting (Ed.).
105. Chen K., et al. Design of asymmetric particles containing a charged interior and a neutral surface charge: comparative study on in vivo circulation of polyelectrolyte microgels. J. Am. Chem. Soc. 2014, 136:9947-9952.
106. Ansorge S., et al. Recent progress in lentiviral vector mass production. Biochem. Eng. J. 2010, 48:362-377.
107. DeMuth P.C., et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat. Mater. 2013, 12:367-376.
108. Shah N.J., et al. Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:12847-12852.
109. Castleberry S.A., et al. Capillary flow layer-by-layer: a microfluidic platform for the high-throughput assembly and screening of nanolayered film libraries. ACS Nano 2014, 8:6580-6589.
110. Min J., et al. Tunable staged release of therapeutics from layer-by-layer coatings with clay interlayer barrier. Biomaterials 2014, 35:2507-2517.
111. Liang W., et al. Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus. Mol. Pharm. 2015, 12:910-921.
112. Ohtake S., et al. Formulation and stabilization of Francisella tularensis live vaccine strain. J. Pharm. Sci. 2011, 100:3076-3087.
113. Kandamchira A., et al. Dielectric behaviour and conformational stability of collagen on interaction with DNA. Int. J. Biol Macromol. 2012, 51:635-639.
114. Lorincz O., et al. Structure and biological activity of pathogen-like synthetic nanomedicines. Nanomedicine-Uk 2012, 8:497-506.
115. van der Heijden I., et al. Long term stability of lyophilized plasmid DNA pDERMATT. Int. J. Pharm. 2013, 453:648-650.
116. Ayen W.Y., Kumar N. A systematic study on lyophilization process of polymersomes for long-term storage using doxorubicin-loaded (PEG)(3)-PLA nanopolymersomes. Eur. J. Pharm. Sci. 2012, 46:405-414.